Table 1.
Characteristics of TOPCAT Participants With and Without Urine Proteomics Data
| Characteristic | Participants without urine proteomic samples (n=3016) | Participants with urine proteomic samples (n=426) |
|---|---|---|
| Demographic characteristics | ||
| Age, y | 69 (61–76) | 69 (61–77) |
| Female sex | 1587 (52.3) | 196 (46) |
| Race | ||
| White | 2668 (88.46) | 391 (91.78) |
| Black | 274 (9.08) | 28 (6.57) |
| Asian | 16 (0.53) | 3 (0.70) |
| Other | 67 (2.22) | 3 (0.70) |
| Location | ||
| Americas | 1535 (50.90%) | 230 (53.99%) |
| Eastern Europe | 1481 (49.10%) | 196 (46.01%) |
| Systolic BP, mm Hg | 130 (120–140) | 128 (120–134) |
| Diastolic BP, mm Hg | 80 (70–81) | 75 (68–80) |
| eGFR, mL/min per 1.73 m2 | 65.4 (53.7–79.3) | 65.7 (53.7–77.9) |
| BMI, kg/m2 | 30.8 (27.1–35.6) | 32 (27.8–36.4) |
| Randomized to spironolactone arm | 1524 (50.53%) | 198 (46.48%) |
| Medical history | ||
| Myocardial infarction | 757 (25.11) | 136 (31.92) |
| Stroke | 234 (7.76) | 31 (7.28) |
| COPD | 349 (11.58) | 54 (12.68) |
| Hypertension | 2742 (90.95) | 404 (94.84) |
| Atrial fibrillation | 1033 (34.26) | 180 (42.25) |
| Diabetes | 980 (32.50) | 138 (32.39) |
| Medication use | ||
| β‐Blockers | 2334 (77.41) | 342 (80.28) |
| Calcium channel blocker | 1141 (37.84) | 152 (35.68) |
| ACE/ARB use | 2558 (84.84) | 341 (80.05) |
| Aspirin use | 1972 (65.41) | 278 (65.26) |
| Statin use | 1528 (50.68) | 277 (65.02) |
Values represent median (interquartile range) or n (percent). ACE indicates angiotensin‐converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; and TOPCAT, Treatment of Preserved Cardiac Function HF With an Aldosterone Antagonist Trial.